US20060074106A1 - Treatment of inflammatory disorders - Google Patents
Treatment of inflammatory disorders Download PDFInfo
- Publication number
- US20060074106A1 US20060074106A1 US11/290,944 US29094405A US2006074106A1 US 20060074106 A1 US20060074106 A1 US 20060074106A1 US 29094405 A US29094405 A US 29094405A US 2006074106 A1 US2006074106 A1 US 2006074106A1
- Authority
- US
- United States
- Prior art keywords
- mefloquine
- treatment
- inflammatory disease
- erythro
- rheumatoid arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 10
- 238000011282 treatment Methods 0.000 title claims description 10
- 229960001962 mefloquine Drugs 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 201000008482 osteoarthritis Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 10
- 229960003677 chloroquine Drugs 0.000 description 10
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 239000003430 antimalarial agent Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 6
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 6
- 229960004171 hydroxychloroquine Drugs 0.000 description 6
- 230000000078 anti-malarial effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- XEEQGYMUWCZPDN-SWLSCSKDSA-N (+)-(11R,2'S)-erythro-mefloquine Chemical compound C([C@H]1[C@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-SWLSCSKDSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 210000002184 nasal cartilage Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- This invention relates to the treatment of inflammatory disorders.
- Cytokines belong to a large group of polypeptide- or glycopeptide-signaling molecules that act, at extremely low concentrations, as regulators of cell growth and essential mediators of inflammation and immune reactions.
- the production and functions of cytokines are tightly regulated by cytokines themselves and by several other factors.
- Most cytokines act locally and are implicated in a number of inflammatory conditions. These include rheumatoid arthritis (RA), osteoarthritis (OA), psoriatic arthritis, psoriasis, ulcerative colitis and Crohn's disease.
- the antimalarial compounds chloroquine and hydroxychloroquine are known as broadly active, modestly potent inhibitors of cytokines.
- Such antimalarial agents have become important disease-modifying antirheumatic agents (DMARD) in the second line treatment of rheumatoid arthritis and other inflammatory disorders.
- Other agents in this class include gold, penicillamine, methotrexate and cyclosporins, all of which have potent activity.
- DMARD disease-modifying antirheumatic agents
- Other agents in this class include gold, penicillamine, methotrexate and cyclosporins, all of which have potent activity.
- the antimalarial agents in the DMARD class are recognised as having a more moderate side-effect profile, while possibly lacking the potency of some of the other agents.
- mefloquine is one of the most effective drugs indicated for both prophylaxis and treatment and has particular utility for use in chloroquine-resistant malaria.
- Chloroquine has been the mainstay of antimalarial treatment and prophylaxis, but the emergence of chloroquine resistance in Plasmodium falciparum , the most lethal strain, has started to limit its utility.
- mefloquine has emerged as the preferred compound for the prophylaxis and treatment of malignant malaria.
- Mefloquine enantiomers have been evaluated in animal models for efficacy against Plasmodium species. These studies concluded that there was no difference in antimalarial potency of the enantiomers.
- (+)-mefloquine possesses potent anti-rheumatic properties.
- the use of the substantially pure enantiomer may maximise efficacy and reduce unwanted side-effects.
- (+)-Erythro-mefloquine is a more potent inhibitor of cytokines implicated in the inflammatory response.
- (+)-Erythro-mefloquine suppresses human lymphocyte proliferation.
- the present invention is based, at least in part, on the finding that mefloquine shows a broad profile of cytokine inhibition, consistent with antimalarial RA therapy.
- mefloquine shows a broad profile of cytokine inhibition, consistent with antimalarial RA therapy.
- isomers of mefloquine show good activity against Interleukin-8 (IL-8). Both chloroquine and hydroxychloroquine are inactive against IL-8, and this cytokine is implicated in the progression of inflammation and tissue destruction inherent in the progress of RA and OA. This is a significant aspect of the enhanced profile of mefloquine isomers in the treatment of inflammatory conditions.
- the active agent may be formulated, e.g. together with a carrier, excipient or diluent, and administered, by procedures that are known in the art, including those already proposed for the racemate.
- Suitable compositions will depend on the intended route of administration, which may be, for example, oral, topical, nasal, rectal, sublingual, buccal or transdermal. Sustained, delayed, timed or immediate release compositions may be used.
- the amount of the agent that should be administered can readily be determined by the skilled man, taking into account the usual factors such as the type of patient, the nature of the condition being treated, and the route of administration.
- the amount of enantiomer may be higher or the same as that for the racemate, or may be modified depending on the co-administration of other drugs.
- Conditions that may be treated include conditions involving cartilage destruction, inflammatory conditions and those mediated by IL-2 and IL-6, e.g. rheumatoid arthritis, asthma, psoriasis, psoriatic arthritis, Crohn's disease, irritable bowel syndrome and systemic lupus erythematosus. Other relevant conditions are ulcerative colitis, COPD and asthma.
- the patient may be disposed to CNS side-effects, and/or may be undergoing concomitant therapy with another drug.
- a mixture e.g. racemate, or substantially one enantiomer.
- the desired enantiomer may be in at least 50%, 70%, 90%, 95% or 99% excess, with respect to any other.
- the active agent may be used in any active form, e.g. salt or non-salt.
- (+)-erythro-mefloquine is preferred. It appears that this compound is particularly useful in providing the desired effect, without tissue destruction, and can be safely administered at a relatively high dosage.
Abstract
A method of treating an inflammatory disease or an autoimmune disease in a subject, comprises the administration of mefloquine.
Description
- This invention relates to the treatment of inflammatory disorders.
- Cytokines belong to a large group of polypeptide- or glycopeptide-signaling molecules that act, at extremely low concentrations, as regulators of cell growth and essential mediators of inflammation and immune reactions. The production and functions of cytokines are tightly regulated by cytokines themselves and by several other factors. Most cytokines act locally and are implicated in a number of inflammatory conditions. These include rheumatoid arthritis (RA), osteoarthritis (OA), psoriatic arthritis, psoriasis, ulcerative colitis and Crohn's disease.
- The antimalarial compounds chloroquine and hydroxychloroquine are known as broadly active, modestly potent inhibitors of cytokines. Such antimalarial agents have become important disease-modifying antirheumatic agents (DMARD) in the second line treatment of rheumatoid arthritis and other inflammatory disorders. Other agents in this class include gold, penicillamine, methotrexate and cyclosporins, all of which have potent activity. However, the utility of these latter drugs for the treatment of a chronic disease such as rheumatoid arthritis is limited by serious side-effects. The antimalarial agents in the DMARD class are recognised as having a more moderate side-effect profile, while possibly lacking the potency of some of the other agents. However, there is still concern about the ocular side-effects of both chloroquine and hydroxychloroquine. Thus, it may be postulated that a drug for the treatment of arthritis that possesses an improved efficacy versus side-effect profile over hydroxychloroquine, the most significant antimalarial drug in the DMARD class, would be of significant clinical potential.
- In terms of antimalarial potency, mefloquine is one of the most effective drugs indicated for both prophylaxis and treatment and has particular utility for use in chloroquine-resistant malaria. Chloroquine has been the mainstay of antimalarial treatment and prophylaxis, but the emergence of chloroquine resistance in Plasmodium falciparum, the most lethal strain, has started to limit its utility. Thus mefloquine has emerged as the preferred compound for the prophylaxis and treatment of malignant malaria.
- Mefloquine enantiomers have been evaluated in animal models for efficacy against Plasmodium species. These studies concluded that there was no difference in antimalarial potency of the enantiomers.
- Surprisingly, it has been found that (+)-mefloquine possesses potent anti-rheumatic properties. The use of the substantially pure enantiomer may maximise efficacy and reduce unwanted side-effects. (+)-Erythro-mefloquine is a more potent inhibitor of cytokines implicated in the inflammatory response. (+)-Erythro-mefloquine suppresses human lymphocyte proliferation.
- The present invention is based, at least in part, on the finding that mefloquine shows a broad profile of cytokine inhibition, consistent with antimalarial RA therapy. In addition, it has been shown that the isomers of mefloquine show good activity against Interleukin-8 (IL-8). Both chloroquine and hydroxychloroquine are inactive against IL-8, and this cytokine is implicated in the progression of inflammation and tissue destruction inherent in the progress of RA and OA. This is a significant aspect of the enhanced profile of mefloquine isomers in the treatment of inflammatory conditions. In addition, as shown in Table 1, the isomers of mefloquine have superior activity over chloroquine and hydroxychloroquine against IL-2, a cytokine implicated in the destruction of connective tissue in RA and OA.
TABLE 1 Inhibition Profile (IC50, μM) T-cell prolifer- IFN TNF IL-1 IL-6 IL-8 IL-2 ation gamma Hydroxy- 32.2 21 90 Inactive 94 16 94 chloroquine Chloroquine 21 6.3 81 Inactive 66 13 63 (−)Mefloquine 18 79 43 63 17 10 18 (+)Mefloquine 24 68 53 41 17 11 17 - This inhibition profile has shown significant activity in a preclinical, ex vivo assay of tissue destruction in the bovine nasal cartilage model. The results are shown in Table 2.
TABLE 2 Inhibition of IL-2-stimulated bovine nasal cartilage destruction 1 μM 10 μM 100 μM Hydroxychloroquine 4 3 36 Chloroquine 3 6 35 (+/−)Mefloquine 20 (−)Mefloquine 37 45 82 (+)Mefloquine 32 44 71 - For use in the invention, the active agent may be formulated, e.g. together with a carrier, excipient or diluent, and administered, by procedures that are known in the art, including those already proposed for the racemate. Suitable compositions will depend on the intended route of administration, which may be, for example, oral, topical, nasal, rectal, sublingual, buccal or transdermal. Sustained, delayed, timed or immediate release compositions may be used.
- The amount of the agent that should be administered can readily be determined by the skilled man, taking into account the usual factors such as the type of patient, the nature of the condition being treated, and the route of administration. The amount of enantiomer may be higher or the same as that for the racemate, or may be modified depending on the co-administration of other drugs.
- Conditions that may be treated include conditions involving cartilage destruction, inflammatory conditions and those mediated by IL-2 and IL-6, e.g. rheumatoid arthritis, asthma, psoriasis, psoriatic arthritis, Crohn's disease, irritable bowel syndrome and systemic lupus erythematosus. Other relevant conditions are ulcerative colitis, COPD and asthma. The patient may be disposed to CNS side-effects, and/or may be undergoing concomitant therapy with another drug.
- Depending on the relative activities of the individual enantiomers, it may be preferred to administer a mixture, e.g. racemate, or substantially one enantiomer. The desired enantiomer may be in at least 50%, 70%, 90%, 95% or 99% excess, with respect to any other. The active agent may be used in any active form, e.g. salt or non-salt.
- The use of (+)-erythro-mefloquine is preferred. It appears that this compound is particularly useful in providing the desired effect, without tissue destruction, and can be safely administered at a relatively high dosage.
Claims (7)
1. Use of (+)-erythro-mefloquine, substantially free of (−)-erythro-mefloquine, for the manufacture of a medicament for the treatment of an inflammatory disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, ulcerative colitis, COPD and asthma.
2. The use, according to claim 1 , wherein the inflammatory disease is rheumatoid arthritis.
3. The use, according to claim 1 , wherein the inflammatory disease is osteoarthritis.
4. A method for treating an inflammatory disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, ulcerative colitis, COPD and asthma, wherein said method comprises administering, to a patient in need of such treatment, (+)-erythro-mefloquine, substantially free of (−)-erythro-mefloquine.
5. The method, according to claim 4 , wherein the inflammatory disease is rheumatoid arthritis.
6. The method, according to claim 4 , wherein the inflammatory disease is osteoarthritis.
7. The method, according to claim 4 , further comprising first identifying said patient in need.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/290,944 US20060074106A1 (en) | 2000-09-05 | 2005-11-30 | Treatment of inflammatory disorders |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0021776.0 | 2000-09-05 | ||
| GBGB0021776.0A GB0021776D0 (en) | 2000-09-05 | 2000-09-05 | The treatment of inflammatory disorders |
| PCT/GB2001/003924 WO2002019994A2 (en) | 2000-09-05 | 2001-08-31 | The treatment of inflammatory disorders |
| US10/362,784 US7034028B2 (en) | 2000-09-05 | 2001-08-31 | Treatment of inflammatory disorders |
| US11/290,944 US20060074106A1 (en) | 2000-09-05 | 2005-11-30 | Treatment of inflammatory disorders |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2001/003924 Continuation WO2002019994A2 (en) | 2000-09-05 | 2001-08-31 | The treatment of inflammatory disorders |
| US10/362,784 Continuation US7034028B2 (en) | 2000-09-05 | 2001-08-31 | Treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20060074106A1 true US20060074106A1 (en) | 2006-04-06 |
Family
ID=9898880
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/362,784 Expired - Fee Related US7034028B2 (en) | 2000-09-05 | 2001-08-31 | Treatment of inflammatory disorders |
| US11/290,944 Abandoned US20060074106A1 (en) | 2000-09-05 | 2005-11-30 | Treatment of inflammatory disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/362,784 Expired - Fee Related US7034028B2 (en) | 2000-09-05 | 2001-08-31 | Treatment of inflammatory disorders |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7034028B2 (en) |
| EP (1) | EP1315496B1 (en) |
| JP (1) | JP2004508323A (en) |
| CN (1) | CN1309388C (en) |
| AT (1) | ATE302008T1 (en) |
| AU (2) | AU2001284234B2 (en) |
| BR (1) | BR0113646A (en) |
| CA (1) | CA2419601A1 (en) |
| DE (1) | DE60112768T2 (en) |
| DK (1) | DK1315496T3 (en) |
| ES (1) | ES2245372T3 (en) |
| GB (1) | GB0021776D0 (en) |
| HK (1) | HK1054324A1 (en) |
| HU (1) | HUP0300934A2 (en) |
| IL (1) | IL154419A0 (en) |
| MX (1) | MXPA03001920A (en) |
| NO (1) | NO323227B1 (en) |
| NZ (1) | NZ524099A (en) |
| PL (1) | PL364030A1 (en) |
| PT (1) | PT1315496E (en) |
| WO (1) | WO2002019994A2 (en) |
| ZA (1) | ZA200301139B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012006315A2 (en) * | 2010-07-07 | 2012-01-12 | Polymedix, Inc. | Methods of immune modulation |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0021776D0 (en) * | 2000-09-05 | 2000-10-18 | Arakis Ltd | The treatment of inflammatory disorders |
| GB0406014D0 (en) * | 2004-03-17 | 2004-04-21 | Arakis Ltd | Pharmaceutical composition and use |
| WO2006108666A1 (en) * | 2005-04-13 | 2006-10-19 | Proteosys Ag | Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases |
| US20100144827A1 (en) * | 2006-12-20 | 2010-06-10 | Medwell Laboratories Ltd. C/O Ngt Technological Incubator | Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof |
| CN113578299B (en) * | 2020-04-30 | 2023-11-10 | 中国石油化工股份有限公司 | Silicon-aluminum-zirconium composite oxide, catalytic cracking catalyst, and preparation methods and applications thereof |
| CN114452289B (en) * | 2020-12-31 | 2023-06-09 | 兰州大学 | Application of quinoline derivatives in preparation of medicines for preventing and/or treating gastrointestinal diseases |
| CN114796216A (en) * | 2022-01-04 | 2022-07-29 | 南京医科大学 | Application of mefloquine in preventing and treating systemic metabolic inflammation diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776977A (en) * | 1992-01-16 | 1998-07-07 | Hoechst Aktiengesellschaft | Arylcycloalkyl derivatives, their production and their use |
| US6197788B1 (en) * | 1997-11-26 | 2001-03-06 | Vernalis Research Limited | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders |
| US6572858B1 (en) * | 1999-04-30 | 2003-06-03 | Apt Pharmaceuticals, Llc | Uses for anti-malarial therapeutic agents |
| US7034028B2 (en) * | 2000-09-05 | 2006-04-25 | Arakis Ltd. | Treatment of inflammatory disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8907518A (en) * | 1988-06-30 | 1991-05-28 | Michael H Davis | PROCESS TO INHIBIT HUMAN IMMUNODEFICIENCY VIRUS (HIV) ACTIVITY |
| ES2118557T3 (en) * | 1994-03-09 | 1998-09-16 | Pfizer | ISOXAZOLINE COMPOUNDS AS INHIBITORS OF TNF RELEASE. |
| DE69808440T2 (en) | 1997-03-07 | 2003-07-10 | Vernalis Res Ltd | USE OF (+) MEFLOQUINE FOR TREATING MALARIA |
-
2000
- 2000-09-05 GB GBGB0021776.0A patent/GB0021776D0/en not_active Ceased
-
2001
- 2001-08-31 ES ES01963202T patent/ES2245372T3/en not_active Expired - Lifetime
- 2001-08-31 JP JP2002524479A patent/JP2004508323A/en active Pending
- 2001-08-31 US US10/362,784 patent/US7034028B2/en not_active Expired - Fee Related
- 2001-08-31 EP EP01963202A patent/EP1315496B1/en not_active Expired - Lifetime
- 2001-08-31 PL PL01364030A patent/PL364030A1/en not_active Application Discontinuation
- 2001-08-31 AT AT01963202T patent/ATE302008T1/en not_active IP Right Cessation
- 2001-08-31 AU AU2001284234A patent/AU2001284234B2/en not_active Ceased
- 2001-08-31 HU HU0300934A patent/HUP0300934A2/en unknown
- 2001-08-31 CN CNB018152023A patent/CN1309388C/en not_active Expired - Fee Related
- 2001-08-31 PT PT01963202T patent/PT1315496E/en unknown
- 2001-08-31 NZ NZ524099A patent/NZ524099A/en unknown
- 2001-08-31 WO PCT/GB2001/003924 patent/WO2002019994A2/en active IP Right Grant
- 2001-08-31 MX MXPA03001920A patent/MXPA03001920A/en active IP Right Grant
- 2001-08-31 AU AU8423401A patent/AU8423401A/en active Pending
- 2001-08-31 IL IL15441901A patent/IL154419A0/en unknown
- 2001-08-31 DK DK01963202T patent/DK1315496T3/en active
- 2001-08-31 BR BR0113646-1A patent/BR0113646A/en not_active IP Right Cessation
- 2001-08-31 DE DE60112768T patent/DE60112768T2/en not_active Expired - Fee Related
- 2001-08-31 CA CA002419601A patent/CA2419601A1/en not_active Abandoned
-
2003
- 2003-02-11 ZA ZA200301139A patent/ZA200301139B/en unknown
- 2003-03-03 NO NO20030985A patent/NO323227B1/en unknown
- 2003-09-03 HK HK03106286A patent/HK1054324A1/en not_active IP Right Cessation
-
2005
- 2005-11-30 US US11/290,944 patent/US20060074106A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776977A (en) * | 1992-01-16 | 1998-07-07 | Hoechst Aktiengesellschaft | Arylcycloalkyl derivatives, their production and their use |
| US6197788B1 (en) * | 1997-11-26 | 2001-03-06 | Vernalis Research Limited | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders |
| US6572858B1 (en) * | 1999-04-30 | 2003-06-03 | Apt Pharmaceuticals, Llc | Uses for anti-malarial therapeutic agents |
| US7034028B2 (en) * | 2000-09-05 | 2006-04-25 | Arakis Ltd. | Treatment of inflammatory disorders |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012006315A2 (en) * | 2010-07-07 | 2012-01-12 | Polymedix, Inc. | Methods of immune modulation |
| WO2012006315A3 (en) * | 2010-07-07 | 2012-04-19 | Polymedix, Inc. | Methods of immune modulation |
| CN103108632A (en) * | 2010-07-07 | 2013-05-15 | 波利梅伊公司 | Methods of immune modulation |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1315496B1 (en) | 2005-08-17 |
| DK1315496T3 (en) | 2005-11-14 |
| BR0113646A (en) | 2004-01-06 |
| DE60112768T2 (en) | 2006-02-02 |
| NZ524099A (en) | 2004-04-30 |
| HUP0300934A2 (en) | 2003-11-28 |
| NO20030985D0 (en) | 2003-03-03 |
| AU8423401A (en) | 2002-03-22 |
| US7034028B2 (en) | 2006-04-25 |
| JP2004508323A (en) | 2004-03-18 |
| ES2245372T3 (en) | 2006-01-01 |
| CN1309388C (en) | 2007-04-11 |
| PL364030A1 (en) | 2004-12-13 |
| US20040029916A1 (en) | 2004-02-12 |
| AU2001284234B2 (en) | 2004-11-04 |
| WO2002019994A3 (en) | 2002-05-16 |
| CN1452488A (en) | 2003-10-29 |
| NO323227B1 (en) | 2007-02-05 |
| ATE302008T1 (en) | 2005-09-15 |
| EP1315496A2 (en) | 2003-06-04 |
| CA2419601A1 (en) | 2002-03-14 |
| IL154419A0 (en) | 2003-09-17 |
| MXPA03001920A (en) | 2004-02-12 |
| WO2002019994A2 (en) | 2002-03-14 |
| DE60112768D1 (en) | 2005-09-22 |
| PT1315496E (en) | 2005-11-30 |
| ZA200301139B (en) | 2004-03-29 |
| GB0021776D0 (en) | 2000-10-18 |
| NO20030985L (en) | 2003-03-03 |
| HK1054324A1 (en) | 2003-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060074106A1 (en) | Treatment of inflammatory disorders | |
| KR100358373B1 (en) | An aqueous suspension of 9-hydroxyrisperidone fatty acid ester | |
| RU2006122179A (en) | METHOD FOR TREATING NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS | |
| TNSN05037A1 (en) | HETEROBIARYLIC DERIVATIVES AS INHIBITORS OF METALLOPROTEINASES OF MATRIX | |
| JPH06500078A (en) | TNF inhibitor | |
| WO2006074265A2 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
| DE69333632T2 (en) | SUBSTITUTED AMINO ALKYL COMPOUNDS | |
| JP2010047609A (en) | Pharmaceutical composition active in reducing production of mcp-1 protein | |
| JPH0465050B2 (en) | ||
| CA2505874A1 (en) | Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease | |
| AU2001284234A1 (en) | The treatment of inflammatory disorders | |
| CZ285633B6 (en) | Use of indole derivatives for preparing medicaments | |
| US20040220221A1 (en) | Treatment of degenerative diseases | |
| US20070202503A1 (en) | Pharmaceutical Composition Of (+)-Erythro-Mefloquine And Its Use | |
| JP2002541190A (en) | Use of osanetant to manufacture a medicament for treating mood disorders | |
| JPS6231688B2 (en) | ||
| Ward et al. | Dihydroergotamine suppositories in a headache clinic | |
| JP2005314347A (en) | Sharp pain inhibitor | |
| JP3953552B2 (en) | Antagonistic inhibitor of transcription factor AP-1 | |
| US5441962A (en) | Method for treating hyperlipemia | |
| RU2184542C2 (en) | 1-phenyl-1-cyclopentyl-4-piperidino-2 butin-1-ola hydrochloride possessing activity in treating and preventing parkinsonism | |
| IL253726B2 (en) | Prevention or treatment of uric acid or gout disease | |
| EP0663822A1 (en) | Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine | |
| KR970020107A (en) | Pharmaceutical preparations for the treatment of acute and chronic inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SOSEI R&D LTD., UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:ARAKIS LIMITED;REEL/FRAME:018826/0339 Effective date: 20060615 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |